Figure 1.
Figure 2:
Sociodemographic and clinical characteristics of study participants
| VARIABLE | FREQUENCY(N=55) | PERCENTAGE(%) |
|---|---|---|
| Age group | ||
| Below 5 years | 14 | 25.5% |
| 5–18 years | 34 | 61.8% |
| Above 18 years | 7 | 12.7% |
| Median age (IQR) | 8 (4,14) | |
| Area of residence | ||
| Dar es Salaam | 28 | 50.9% |
| Outside Dar es Salaam | 27 | 49.1% |
| Haemophilia severity | ||
| Severe (<1%) | 28 | 50.9% |
| Moderate (1–5%) | 22 | 40.0% |
| Mild (6–40%) | 4 | 7.3% |
| Unknown | 1 | 1.8% |
| History of inhibitors post CFC exposure | ||
| Present | 19 | 34.6% |
| Absent | 36 | 65.4% |
| Pre-emicizumab prophylaxis ABR (median and IQR) | 8(5,16) | |
| Target joint prior to prophylaxis | ||
| Present | 19 | 34.6% |
| Absent | 36 | 65.4% |
Association between sociodemographic and clinical characteristics and spontaneous bleeding
| VARIABLE | SPONTANEOUS BLEEDING | UNIVARIABLE ANALYSIS | ||||
|---|---|---|---|---|---|---|
| YES (%) | NO (%) | P VALUE | APR | 95%CI | P VALUE | |
| Age group (years) | ||||||
| < 5 | 1 (7.1%) | 13 (92.9%) | < 0.0001 | Ref | ||
| 5–18 | 5 (15.2%) | 28 (84.8%) | 2.12 | 0.27–16.54 | 0.473 | |
| >18 | 5 (83.3%) | 1 (16.7%) | 11.67 | 1.71–79.76 | 0.012 | |
| Severity of haemophilia | ||||||
| Mild | 1 (25.0%) | 3 (75.0%) | 0.885 | Ref | ||
| Moderate | 4 (18.2%) | 18 (81.8%) | 0.73 | 0.11–4.94 | 0.744 | |
| Severe | 6 (23.1%) | 20 (76.9%) | 0.92 | 0.15–5.79 | 0.932 | |
| Cumulative adherence | ||||||
| Adherence | 6 (14.6%) | 35 (85.4%) | 0.098 | 0.35 | 0.13–0.95 | 0.040 |
| Non-adherence | 5 (41.7%) | 7 (58.3%) | Ref | |||
| Residence | ||||||
| Dar-es-Salaam | 5 (19.2%) | 21 (80.8%) | 1.000 | Ref | ||
| Outside Dar-es-Salaam | 6 (22.2%) | 21 (77.8%) | 1.16 | 0.40–3.33 | 0.789 | |
| Mode of payment | ||||||
| Exemption | 0 (0.0%) | 1 (100.0%) | 1.000 | 0.80 | 0.68–0.95 | 0.010 |
| Insured | 7 (23.3%) | 23 (76.7%) | 0.99 | 0.80–1.22 | 0.900 | |
| Private | 2 (25.0%) | 6 (75.0%) | 1.00 | 0.75–1.34 | 1.000 | |
| Public (cost sharing) | 4 (25.0%) | 12 (75.0%) | Ref | |||